Evidence map›Paper›PMID 41267643›Full record

ArticleThe Australian & New Zealand journal of obstetrics & gynaecology2026

The Sociodemographic Benefits of Extending MS-2Step to 70 Days in Australia.

Laura Slade, Jennie Louise, Katina D'Onise, Jodie Dodd

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Australian & New Zealand journal of obstetrics & gynaecology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Laura SladeWomen's and Children's Hospital, North Adelaide, South Australia, Australia.ORCID 0000-0001-8425-9359
Jennie LouiseWomen's and Children's Hospital Research Institute, Women's and Children's Hospital, North Adelaide, South Australia, Australia.
Katina D'OniseSchool of Public Health, University of Adelaide, Adelaide, South Australia, Australia.
Jodie DoddWomen's and Children's Hospital, North Adelaide, South Australia, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In many areas of the world, outpatient early medical abortion (EMA) is provided through mifepristone and misoprostol up to 10 weeks or 70 days gestation; however in Australia access is restricted to 63 days. A retrospective cohort study using South Australian data from 2012 to 2020 compares women undergoing abortion at less than 9 weeks with women undergoing abortion at less than 10 weeks. Currently, socioeconomic disadvantage is associated with a higher rate of presenting for abortion after 9 weeks. Extending EMA access would be of particular benefit for groups with socioeconomic disadvantage.

Indexed as

Abortifacient Agents, NonsteroidalAbortion, InducedHealth Services AccessibilityMifepristoneMisoprostolAdultAustraliaFemaleGestational AgeHumansPregnancyPregnancy Trimester, FirstRetrospective StudiesSocioeconomic FactorsYoung AdultAbortifacient Agents, NonsteroidalMifepristoneMisoprostolabortion accessmaternal healthtermination of pregnancy

Identifiers

PMID41267643
PMCPMC12920048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.